Haiyan Su1, Xudong Ma2, Yiqun Huang2, Huidan Han2, Yong Zou2, Wenhua Huang3. 1. Department of Pathology, Zhangzhou Affiliated Hospital of Fujian Medical University Zhangzhou, Fujian, China. 2. Department of Hematology Zhangzhou Affiliated Hospital of Fujian Medical University Zhangzhou, Fujian, China. 3. School of Basic Medical Sciences, Southern Medical University Guangzhou, China.
Abstract
AIMS: To investigate the involvement of JARID1B histone methyltransferase in the epigenetic change of euchromatic promoter in mantle cell lymphoma (MCL) and acute leukemia. METHODS: We retrospectively analyzed the protein of JARID1B and tri-methylated histone H3 lysine 4 (H3K4), histone H3 lysine 9 (H3K9), and cyclin D1 and Ki67 in 30 cases of MCL by immunohistochemistry. JARID1B was depleted by small interfering RNA (siRNA), and cell apoptosis and cell proliferation were detected by flow cytometry and MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide], histone tri-methylated H3K4 and histone acetylated H3, H4, cyclin D1, Bcl-2, procaspase-3, C-myc were studied by Western blot. RESULTS: We demonstrated that JARID1B was upregulated and histone tri-methylated H3K4 was downregulated in MCL compared to proliferative lymphadenitis, P < 0.05. The expression of histone methylated H3K9 was similar in both. Histone methylation of H3K4 was positively correlated with Ki67 in MCL (Kappa = 0.757, P < 0.05). This study showed that depletion of JARID1B cleavage apoptotic proteins of Bcl-2, procaspase-3, C-myc and resulted in loss cell viability and inducing apoptosis in Jeko-1 and HL-60 cell lines. JARID1B siRNA improved tri-methyl H3K4 and histone acetylated H3 and inhibited cyclin D1, but did not affect histone acetylated H4. CONCLUSIONS: This study revealed hyper JARID1B expression and hypo histone H3K4 tri-methylation in MCL. We identify depletion JARID1B as a demethylase which is capable of removing three methyl groups from H3K4 and up-regulating histone acetylation of H3 in both cell lines. Interestingly, depletion of JARID1B inhibits Cyclin D1, which is one of the genes contributes to MCL pathogenesis. JARID1B might be one of therapeutic targets in acute leukemia and MCL.
AIMS: To investigate the involvement of JARID1B histone methyltransferase in the epigenetic change of euchromatic promoter in mantle cell lymphoma (MCL) and acute leukemia. METHODS: We retrospectively analyzed the protein of JARID1B and tri-methylated histone H3 lysine 4 (H3K4), histone H3 lysine 9 (H3K9), and cyclin D1 and Ki67 in 30 cases of MCL by immunohistochemistry. JARID1B was depleted by small interfering RNA (siRNA), and cell apoptosis and cell proliferation were detected by flow cytometry and MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide], histone tri-methylated H3K4 and histone acetylated H3, H4, cyclin D1, Bcl-2, procaspase-3, C-myc were studied by Western blot. RESULTS: We demonstrated that JARID1B was upregulated and histone tri-methylated H3K4 was downregulated in MCL compared to proliferative lymphadenitis, P < 0.05. The expression of histone methylated H3K9 was similar in both. Histone methylation of H3K4 was positively correlated with Ki67 in MCL (Kappa = 0.757, P < 0.05). This study showed that depletion of JARID1B cleavage apoptotic proteins of Bcl-2, procaspase-3, C-myc and resulted in loss cell viability and inducing apoptosis in Jeko-1 and HL-60 cell lines. JARID1B siRNA improved tri-methyl H3K4 and histone acetylated H3 and inhibited cyclin D1, but did not affect histone acetylated H4. CONCLUSIONS: This study revealed hyperJARID1B expression and hypo histone H3K4 tri-methylation in MCL. We identify depletion JARID1B as a demethylase which is capable of removing three methyl groups from H3K4 and up-regulating histone acetylation of H3 in both cell lines. Interestingly, depletion of JARID1B inhibits Cyclin D1, which is one of the genes contributes to MCL pathogenesis. JARID1B might be one of therapeutic targets in acute leukemia and MCL.
Authors: M H Lahoud; S Ristevski; D J Venter; L S Jermiin; I Bertoncello; S Zavarsek; S Hasthorpe; J Drago; D de Kretser; P J Hertzog; I Kola Journal: Genome Res Date: 2001-08 Impact factor: 9.043
Authors: Shigeki Iwase; Fei Lan; Peter Bayliss; Luis de la Torre-Ubieta; Maite Huarte; Hank H Qi; Johnathan R Whetstine; Azad Bonni; Thomas M Roberts; Yang Shi Journal: Cell Date: 2007-02-22 Impact factor: 41.582
Authors: Angela Barrett; Bente Madsen; John Copier; Pei Juan Lu; Lucienne Cooper; Angelo G Scibetta; Joy Burchell; Joyce Taylor-Papadimitriou Journal: Int J Cancer Date: 2002-10-20 Impact factor: 7.396
Authors: Alexander Roesch; Andrea M Mueller; Thomas Stempfl; Christoph Moehle; Michael Landthaler; Thomas Vogt Journal: Int J Cancer Date: 2008-03-01 Impact factor: 7.396
Authors: Michaela S Banck; Side Li; Hitomi Nishio; Cheng Wang; Andreas S Beutler; Martin J Walsh Journal: Epigenetics Date: 2009-02-23 Impact factor: 4.528
Authors: Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh Journal: Oncotarget Date: 2016-07-26